Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1921-1940 of 2,251 trials

Advanced Ovarian Cancer: Relacorilant with Nab-Paclitaxel and Bevacizumab

We are studying a new treatment combination for patients with advanced ovarian, primary peritoneal, or fallopian-tube cancer. The trial aims to evaluate how well this combination works and its safety.

Ovarian, Fallopian Tube, or Peritoneal CancerEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Intranasal Lysine-Aspirin for Respiratory Disease

We are studying the effects of a new nasal treatment on asthma and nasal symptoms in patients with NSAID-exacerbated respiratory disease. The goal is to see if it improves breathing and overall quality of life.

Nonsteroidal Anti-Inflammatory Drug Exacerbated Respiratory Disease (N-ERD)1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Congenital Nephrogenic Diabetes Insipidus: Fluconazole Study

We are testing whether fluconazole can help people with congenital nephrogenic diabetes insipidus reduce excessive urination and improve their quality of life. This study focuses on patients with a specific AVPR2 gene mutation.

Congenital Nephrogenic Diabetes Insipidus≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrology

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: TAK-881 vs. HYQVIA

We are comparing two medications to see if TAK-881 works similarly to HYQVIA in adults with CIDP. This study may help determine the best treatment options for managing this condition.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Nasopharyngeal Cancer: Nivolumab Treatment Study

We are studying the effectiveness of Nivolumab for patients with nasopharyngeal cancer who have progressed after chemotherapy. We also want to understand how safe this treatment is for these patients.

Nasopharyngeal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Throat and Larynx Cancer: Low-Dose Radiation Therapy

We are studying a new treatment combining low doses of radiation and chemotherapy for patients with advanced throat and larynx cancer. The goal is to see if this approach improves treatment outcomes and is well-tolerated.

Throat and Larynx Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOtolaryngology

Breast Cancer Diagnosis: Contrast-Enhanced Spectral Mammography

We are evaluating a new imaging method to see if it improves the accuracy of breast cancer diagnosis. This may help reduce the number of unnecessary biopsies for suspicious lesions.

Breast Lesions6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOtolaryngology

Infantile Spasms: Vigabatrin for High-Risk Children

We are studying whether vigabatrin can prevent infantile spasms in children under 1 year old who are at high risk due to conditions like tuberous sclerosis. This research aims to improve outcomes for these vulnerable infants.

High-Risk Infantile Spasm Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurology

Post-Surgery Pain Management: Comparing Two Techniques

We are studying the effectiveness of two different nerve block methods for pain relief after laparoscopic colon surgery. Our goal is to see if these methods work better than traditional oral pain medications.

Colon Surgery for Cancer or Diverticulosis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngology

Severe Asthma: Tezepelumab Treatment

We are exploring how Tezepelumab may improve airway barrier function in patients with severe asthma, including those with chronic rhinosinusitis. This study looks at the effects of the treatment on the airways' response to harmful substances.

Severe Asthma with Chronic Rhinosinusitis and Nasal PolypsSevere Asthma without Chronic Rhinosinusitis>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesAllergologyOtolaryngologyPulmonology

Neovascular Age-Related Macular Degeneration: Faricimab Injections

We are studying the safety and long-term effectiveness of faricimab injections for people with neovascular age-related macular degeneration. The goal is to see if it improves vision and how well it works over time.

Neovascular Age-Related Macular Degeneration>2 yearsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOphthalmology

ALK-Positive Advanced Lung Cancer: NVL-655 vs. Alectinib

We are studying a new medication, NVL-655, for patients with advanced ALK-positive lung cancer who haven't been treated before. The goal is to see if it works better and is safer than the current standard treatment, alectinib.

Advanced ALK-positive Non-Small Cell Lung CancerConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Severe Asthma: Dupilumab Treatment Study

We are investigating how Dupilumab affects mucus buildup and immune responses in patients with severe asthma. This study aims to improve understanding of asthma management and treatment options.

Severe Asthma>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteAllergologyPulmonology

5-Aminolevulinic Acid (5-ALA) for Brain Tumors in Kids

We are studying the safety of 5-ALA during surgeries for children and adolescents with brain tumors. The trial will help us understand how well it identifies tumor cells and its effects on young patients.

Brain Tumor>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Anesthesia Study: Ketamine vs. Propofol Combinations

We are comparing the effectiveness of ketamine alone and a ketamine-propofol mix against standard propofol for safe tracheal intubation in patients at risk of aspiration during surgery. The goal is to see which option leads to fewer complications and better tolerance.

Rapid Sequence Induction≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPsychiatry

Lung Surgery: Oxygen Delivery Techniques

We are comparing three methods of oxygen administration during lung surgery to see how they affect recovery and complications. This study aims to find the best approach for improving patient outcomes after surgery.

Lung Resection Surgery>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPulmonology

Papillary Craniopharyngioma: Dabrafenib and Trametinib Treatment

We are studying how well the medications dabrafenib and trametinib reduce tumor size in patients with papillary craniopharyngioma. The trial also looks at how these treatments affect quality of life and other health aspects.

Papillary Craniopharyngioma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Surgery and Immune Response: Low-Dose Interferon-alfa2a Study

We are investigating whether low-dose Interferon-alfa2a can improve immune function and recovery in patients undergoing surgery. This study looks at immune cell changes and recovery quality compared to a placebo.

Colon Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Managing High Potassium: Lokelma for Chronic Kidney Disease

We are studying whether Sodium Zirconium Cyclosilicate (Lokelma) can help lower potassium levels in patients with chronic kidney disease. This trial compares it to standard treatments to find the best approach.

High Potassium Levels in Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Advanced Basal Cell Carcinoma: Cemiplimab Treatment Study

We are studying the effectiveness and safety of Cemiplimab for patients with advanced basal cell carcinoma. This trial aims to see how well it works as a first-line treatment and to identify factors that may affect treatment outcomes.

Basal Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology